Lab
Alpha Clinical Laboratory, INC.
Alpha Clinical Laboratory, INC. was paid $9.98M by Medicaid between Jan 2018 and Dec 2024, across 72 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 24% of everything it billed.
33Billing provider infoALPHA CLINICAL LABORATORY, INC.
BURBANK, CA 91504
BURBANK, CA 91504
33aNPI1043352586assigned 02/13/2007
33bProvider typeClinical Medical Laboratory
28Total paid$9.98M
24GClaims497,309
24DCodes billed72
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#75 of 561
Median peer was paid$222K
This provider vs. median45×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 119,987 | $2.73M | |
| 2019 | 59,129 | $1.05M | |
| 2020 | 23,908 | $389K | |
| 2021 | 75,261 | $1.86M | |
| 2022 | 55,924 | $1.69M | |
| 2023 | 72,385 | $1.36M | |
| 2024incomplete | 90,715 | $913K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 24% | 82,844 | 79,859 | $2.44M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 24% | 82,639 | 79,652 | $2.42M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 24% | 39,032 | 28,432 | $2.40M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 11% | 57,403 | 54,592 | $1.14M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.8% | 10,585 | 4,651 | $479K |
| 86592 | 2.7% | 74,847 | 72,069 | $274K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.0% | 17,325 | 11,592 | $197K |
| 80055 | <1% | 2,605 | 2,603 | $83K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,789 | 8,683 | $69K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,096 | 9,909 | $60K |
| 80061 | Lipid panel | <1% | 10,353 | 10,196 | $48K |
| 80053 | Comprehensive metabolic panel | <1% | 11,068 | 10,742 | $44K |
60 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,023 | $42K |
| 84702 | <1% | 3,497 | $41K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,868 | $30K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 389 | $15K |
| 86803 | <1% | 1,820 | $15K | |
| 84481 | <1% | 2,535 | $13K | |
| 84439 | <1% | 3,365 | $12K | |
| 87340 | <1% | 1,952 | $12K | |
| 82607 | <1% | 2,970 | $12K | |
| 84480 | <1% | 2,861 | $11K | |
| 86705 | <1% | 1,444 | $10K | |
| 82746 | <1% | 1,999 | $10K | |
| 84153 | <1% | 1,980 | $8K | |
| 81000 | <1% | 4,474 | $8K | |
| 86708 | <1% | 1,121 | $8K | |
| 82728 | <1% | 1,844 | $8K | |
| 86704 | <1% | 1,063 | $7K | |
| 83090 | <1% | 1,472 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,388 | $7K |
| 86709 | <1% | 963 | $6K | |
| 83735 | <1% | 3,162 | $5K | |
| 83540 | <1% | 2,367 | $5K | |
| 86141 | <1% | 941 | $5K | |
| 82172 | <1% | 615 | $5K | |
| 83550 | <1% | 1,844 | $5K | |
| 87081 | <1% | 784 | $4K | |
| 82550 | <1% | 1,583 | $3K | |
| 87210 | <1% | 708 | $3K | |
| 84550 | <1% | 3,134 | $2K | |
| 86038 | <1% | 922 | $2K | |
| 84436 | <1% | 1,874 | $2K | |
| 82950 | <1% | 426 | $2K | |
| 82947 | <1% | 547 | $1K | |
| 84479 | <1% | 501 | $1K | |
| 86430 | <1% | 1,066 | $1K | |
| 85651 | <1% | 3,960 | $1K | |
| 86696 | <1% | 98 | $1K | |
| 86140 | <1% | 1,163 | $1K | |
| 86695 | <1% | 93 | $825.27 | |
| 83002 | <1% | 40 | $615.14 | |
| 84144 | <1% | 41 | $591.41 | |
| 82248 | <1% | 424 | $545.84 | |
| 82565 | <1% | 1,070 | $540.34 | |
| 83690 | <1% | 409 | $514.72 | |
| 82150 | <1% | 452 | $502.24 | |
| 84100 | <1% | 586 | $449.37 | |
| 86706 | <1% | 80 | $431.56 | |
| 86677 | <1% | 70 | $425.51 | |
| 81002 | <1% | 2,134 | $310.07 | |
| 82465 | <1% | 68 | $225.39 | |
| 87184 | <1% | 77 | $193.14 | |
| 85018 | <1% | 77 | $159.18 | |
| 85013 | <1% | 77 | $156.11 | |
| 86694 | <1% | 13 | $123.72 | |
| 87088 | <1% | 40 | $120.95 | |
| 82977 | <1% | 136 | $87.20 | |
| 85610 | <1% | 30 | $41.61 | |
| 83615 | <1% | 55 | $40.17 | |
| 86850 | <1% | 12 | $28.08 | |
| 83655 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZAMARYAN, YERVAND (CEO)